Adaptimmune Therapeutics's total assets for Q3 2024 were $317.44M, a decrease of -1.33% from the previous quarter. ADAP total liabilities were $237.45M for the fiscal quarter, a 5.33% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.